Mark Leeds, D.O.
Mark Leeds, D.O.
The Sublocade Taper For Getting Off Suboxone: Is This How To Get Off Suboxone?
The Sublocade Taper For Getting Off Suboxone: Is This How To Get Off Suboxone?
The Sublocade Taper For Getting Off Suboxone: Is This How To Get Off Suboxone?
Sunday 18th December 2022
Dr. Mark Leeds examines using Sublocade for tapering off Suboxone, discussing their differences and tapering challenges.
8 minutes
Informative
Educational
Thought-provoking
Non-judgmental
Engaging
About this podcast
Author:
Mark Leeds, D.O.
Overview:
Categories:
Innovative Treatments & Recovery Paths
Sobriety Toolkit
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
381 (View all)
Do you want to link to this podcast?
Get the buttons here!Sublocade vs. Suboxone: Navigating the Tapering Challenge
While subcutaneous, long-acting buprenorphine may show promise as a tapering agent, it is still too early to recommend it for Suboxone patients.
Ever found yourself wondering how to safely transition off Suboxone? In this episode, Dr. Mark Leeds tackles the intriguing concept of using Sublocade as a tapering tool. He kicks things off by breaking down the key differences between Sublocade, a monthly injection, and Suboxone, which comes in sublingual strips or pills. Both medications contain Buprenorphine, but their forms and applications vary significantly. Dr.
Leeds dives into why Sublocade hasn’t yet dethroned Suboxone as the go-to treatment for opioid addiction, despite its potential advantages. One of the major hurdles he highlights is the challenge of tapering off Suboxone, which isn't designed for easy dose reduction. With the smallest dose being 2mg and no option to split tablets or films, patients face a tricky situation. Dr.
Leeds discusses how a gradual taper is crucial to minimize withdrawal symptoms but acknowledges that the current tapering methods are far from perfect. He explores whether Sublocade could be a viable alternative for tapering, though he admits it’s still too early to give a definitive answer. The long-acting nature of Sublocade might hold promise, but it lacks the necessary dosing flexibility for most patients. Wrapping up, Dr.
Leeds calls for better support from medication manufacturers to aid in tapering processes, a need that extends beyond just Suboxone. This episode is a must-listen for anyone grappling with opioid dependence and looking for insights into safer tapering strategies.